Insurers will cover at-home COVID-19 tests starting Saturday

Insurance companies and group health plans will be required to cover the cost of at-home COVID-19 tests beginning Saturday, January 15.

Under direction from the Biden administration, most individuals with private health coverage can buy a test online or at a pharmacy and either receive it free of charge or get reimbursed by submitting a claim. The move entitles patients to eight free over-the-counter tests per month, the administration said Monday.

“This is all part of our overall strategy to ramp up access to easy-to-use, at-home tests at no cost,” HHS Secretary Xavier Becerra added. “By requiring private health plans to cover people’s at-home tests, we are further expanding Americans’ ability to get tests for free when they need them.”

PCR and rapid tests ordered or administered by a healthcare provider will still remain fully covered by insurance with no limitations.

The administration is striving to incentivize private insurers to establish pathways for covering at-home tests upfront, without messy reimbursement processes. This push is part of the president’s ongoing efforts to ramp up testing capabilities in the face of the omicron variant, which includes 500 million rapid tests purchased by the government that were sent out beginning Jan. 1.

One of the nation’s largest insurance groups, Blue Cross Blue Shield, said it supports the administration’s moves, but noted supply issues remain a looming problem. 

“We are concerned that the policy does not solve for the limited supply of tests in the country and could cause additional consumer friction as insurers stand up a program in just four days’ time,” Blue Cross Blue Shield Association President and CEO Kim Keck said in a Jan. 10 statement. “We will continue to partner with the administration and retailers to help make this work and advocate for policies that promote affordable and equitable access.”

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.